The Q4 earnings report for UroGen Pharma (NASDAQ:URGN) was released on Monday, March 2, 2026 at 08:00 AM.

Here's what investors need to know about the latest announcement.

Earnings

UroGen Pharma beat estimated earnings by 5.26%, reporting an EPS of $-0.54 versus an estimate of $-0.57.

Revenue was up $13.27 million from the same period last year.

Earnings History Overview

The company beat on EPS by $0.01 in the previous quarter, leading to a 1.27% drop share price change the next day.

Here's a look at UroGen Pharma's past performance:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	-0.70	-0.83	-0.80	-0.72
EPS Actual	-0.69	-1.05	-0.92	-0.80
Revenue Estimate	31.87M	23.66M	22.70M	25.25M
Revenue Actual	27.50M	24.21M	20.25M	24.57M

To track all earnings releases for UroGen Pharma visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.